Disease · HP_0002829

Arthralgia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Arthralgia. Diseases, record HP_0002829. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0002829

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Arthralgia; Open Targets
Open Targets ID: HP_0002829; Open Targets
Other names: Arthralgias, Joint pain; Open Targets
NCI Thesaurus: C50464; NCI Thesaurus
Highest stage of its drugs: Approval, for 36 of its 57 drugs, from ATC, DailyMed and TTD; Open Targets

Drugs57

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
KETOPROFEN	CHEMBL571	Small molecule	Approval	ATC	3	2	1	Drugs and targets
DICLOFENAC	CHEMBL139	Small molecule	Approval	ATC	2	1	1	Drugs and targets
IBUPROFEN	CHEMBL521	Small molecule	Approval	ATC	2	1	1	Drugs and targets
MECLOFENAMIC ACID	CHEMBL509	Small molecule	Approval	ATC and TTD	2	0	0	Drugs and targets
ACECLOFENAC	CHEMBL93645	Small molecule	Approval	ATC	1	0	0	Drugs and targets
BENDAZAC	CHEMBL1089221	Small molecule	Approval	ATC	1	0	0	Drugs and targets
BENZYDAMINE	CHEMBL12610	Small molecule	Approval	ATC	1	0	0	Drugs and targets
BUFEXAMAC	CHEMBL94394	Small molecule	Approval	ATC	1	0	0	Drugs and targets
CAPSAICIN	CHEMBL294199	Small molecule	Approval	ATC	1	0	0	Drugs and targets
CLOFEZONE	CHEMBL6067984	Small molecule	Approval	ATC	1	0	0	Drugs and targets

1 to 10 of 57

See all 57 drugs

Targets57

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PTGS2	Cyclooxygenase	16	Cyclooxygenase inhibitor; Cyclooxygenase-2 inhibitor	Approval	https://conductscience.org/library/genes/5743	Drugs and targets
PTGS1	Cyclooxygenase	15	Cyclooxygenase inhibitor	Approval	https://conductscience.org/library/genes/5742	Drugs and targets
PGR	Progesterone receptor	2	Progesterone receptor agonist	Unknown	https://conductscience.org/library/genes/5241	Drugs and targets
TRPV1	Transient receptor potential cation channel subfamily V member 1	2	Vanilloid receptor agonist; Vanilloid receptor opener	Approval	https://conductscience.org/library/genes/7442	Drugs and targets
ADRA1A	Adrenergic receptor alpha	1	Adrenergic receptor alpha antagonist	Approval	https://conductscience.org/library/genes/148	Drugs and targets
ADRA1B	Adrenergic receptor alpha	1	Adrenergic receptor alpha antagonist	Approval	https://conductscience.org/library/genes/147	Drugs and targets
ADRA1D	Adrenergic receptor alpha	1	Adrenergic receptor alpha antagonist	Approval	https://conductscience.org/library/genes/146	Drugs and targets
ADRA2A	Adrenergic receptor alpha	1	Adrenergic receptor alpha antagonist	Approval	https://conductscience.org/library/genes/150	Drugs and targets
ADRA2B	Adrenergic receptor alpha	1	Adrenergic receptor alpha antagonist	Approval	https://conductscience.org/library/genes/151	Drugs and targets
ADRA2C	Adrenergic receptor alpha	1	Adrenergic receptor alpha antagonist	Approval	https://conductscience.org/library/genes/152	Drugs and targets

1 to 10 of 57

See all 57 targets

Trials15

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02728752	Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)	Phase 3	95	2021-04-21	Dermatomyositis	HUMAN IMMUNOGLOBULIN G	Its record names the disease	ClinicalTrials.gov
NCT01651806	Weighted Versus Uniform Dose of Tranexamic Acid in Patients Undergoing Primary, Knee Arthroplasty	Phase 2/3	65	2017-12-13	Osteoarthritis, Intraoperative Bleeding	TRANEXAMIC ACID	Its record names the disease	ClinicalTrials.gov
NCT00372333	IDEA-033 Open Label Study	Phase 3	491		Joint Pain, Musculoskeletal Pain, Stiffness, Soft Tissue Inflammation in Designated Target Area(s)	KETOPROFEN	Its record names the disease	ClinicalTrials.gov
NCT01373697	Study to Assess the Efficacy and Safety of Ibuprofen 50 mg/g Gel Compared to Profenid 25mg/g Gel	Phase 3	144		Muscular Atrophy, Sprains, Tendonitis	IBUPROFEN	Its record names the disease	ClinicalTrials.gov
NCT04408560	Evaluation of the Efficacy of a Homeopathic Protocol in Patients With Non-metastatic Breast Cancer	Not applicable	140		Breast Cancer Female, Joint Pain	POISON OAK EXTRACT	Its record names the disease	ClinicalTrials.gov
NCT02778906	Abatacept Reversing Subclinical Inflammation as Measured by MRI in ACPA Positive Arthralgia	Phase 3	98		Arthralgia, Arthritis	ABATACEPT	Its record names the disease	ClinicalTrials.gov
NCT07254637	Tocilizumab in Chronic Inflammatory CPPD Disease	Phase 2	80		Calcium Pyrophosphate Deposition Disease	TOCILIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT04511832	Comparative Effectiveness of Acupuncture and Nonsteroidal Anti-inflammatory Drugs for the Management of Aromatase Inhibitor Induced Arthralgia Among Breast Cancer Survivors	Not applicable	54		Breast Cancer	DICLOFENAC	Its record names the disease	ClinicalTrials.gov
NCT04354649	Immune-Mediated Pathophysiology And Clinical Triage Program	Phase 2	46		Arthritis, Arthralgia	HYDROXYCHLOROQUINE, PREDNISONE	Its record names the disease	ClinicalTrials.gov
NCT00211718	Intra-Articular Injection of Botulinum Toxin Type A for Shoulder Pain	Phase 3	40		Arthritis, Shoulder Pain	BOTULINUM TOXIN TYPE A	Its record names the disease	ClinicalTrials.gov

1 to 10 of 15

See all 15 trials

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Overall Period Octagam vs First Period Placebo: deaths from any cause	0 of 95	0 of 48	143	NCT02728752	Trial comparisons
Overall Period Octagam vs First Period Placebo: serious adverse events	14 of 95	2 of 48	143	NCT02728752	Trial comparisons
Octagam10% vs Placebo: Measure the Number of Patients Who Had an Increase of ≥20 Points on the Total Improvement Score (TIS)	37 of 47	21 of 48	95	NCT02728752	Trial comparisons

Papers from its trials6

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40616720	DERIVED	1	PubMed
39918968	DERIVED	1	PubMed
38233885	DERIVED	1	PubMed
37799613	DERIVED	1	PubMed
36198179	DERIVED	1	PubMed
33429735	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/HP_0002829

GET https://conductscience.org/api/diseases/v1/HP_0002829/drugs?page=2

API reference For AI assistants